Blood Test for Receptor Predicts Prostate Cancer Treatment Response
By LabMedica International staff writers Posted on 21 Sep 2014 |
Image: The ACD RNAscope 2.0 Brown kit for in situ hybridization (Photo courtesy of Advanced Cell Diagnostics).
Prostate cancer patients whose tumors contain a shortened receptor called androgen-receptor splice variant 7 messenger ribonucleic acid (AR-V7) are less likely to respond to two widely used drugs for metastatic prostate cancer.
The detection of AR-V7 in circulating tumor cells may be associated with resistance to enzalutamide and abiraterone in patients with castration-resistant prostate cancer. AR-V7 is the only known androgen-receptor variant encoding a functional protein product that is detectable in clinical specimens.
Scientists at the Johns Hopkins’ Kimmel Cancer Center (Baltimore, MD, USA) evaluated two groups of 31 men with prostate cancer that had spread and whose blood levels of prostate-specific antigen (PSA) were still rising despite low testosterone levels. Investigators gave each man either enzalutamide or abiraterone and tracked whether their PSA levels continued to rise, an indication that the drugs were not working.
Circulating tumor cell (CTC) analyses were conducted using the commercially-available Alere CTC AdnaTest platform (AdnaGen; Langenhagen, Germany). A Prostate Cancer Detect kit was used to make complementary DNA (cDNA) for detection of prostate cancer-associated RNA transcripts using multiplexed polymerase chain reaction (PCR) and the signals were detected by the Agilent Bioanalyzer (Agilent Technologies; Palo Alto, CA, USA). RNA in situ hybridization (RISH) was performed to detect the androgen receptor (AR) and AR-V7 on formalin-fixed paraffin-embedded (FFPE) tissue or cell pellet blocks using the ACD RNAscope 2.0 Brown kit (Advanced Cell Diagnostics; Hayward, CA, USA).
In the enzalutamide group, none of 12 patients whose blood samples tested positive for AR-V7 responded to the drug, compared with 10 responders among 19 men who had no AR-V7 detected. In the abiraterone group, none of six AR-V7-positive patients responded, compared with 17 responders among 25 patients lacking AR-V7. Enzalutamide and abiraterone target proteins called androgen receptors and block the receptors’ ability to activate prostate cancer cells. AR-V7 is a shortened form of the androgen receptor that lacks a binding spot targeted by enzalutamide and abiraterone. AR-V7 is therefore free to manipulate prostate cancer cells’ genetic material, which makes the cancer cells grow and spread.
Emmanuel S. Antonarakis, MD, assistant professor of oncology and lead author of the study said, “Patients whose blood samples contained AR-V7 got no benefit from either enzalutamide or abiraterone. This test could be used before starting enzalutamide or abiraterone therapy, and if the test shows the presence of AR-V7, patients may opt for a different therapy. It could also be used to monitor patients receiving enzalutamide or abiraterone for AR-V7, providing an indication these drugs may not work for much longer.” The study was published on September 3, 2014, in the New England Journal of Medicine.
Related Links:
Johns Hopkins’ Kimmel Cancer Center
AdnaGen
Advanced Cell Diagnostics
The detection of AR-V7 in circulating tumor cells may be associated with resistance to enzalutamide and abiraterone in patients with castration-resistant prostate cancer. AR-V7 is the only known androgen-receptor variant encoding a functional protein product that is detectable in clinical specimens.
Scientists at the Johns Hopkins’ Kimmel Cancer Center (Baltimore, MD, USA) evaluated two groups of 31 men with prostate cancer that had spread and whose blood levels of prostate-specific antigen (PSA) were still rising despite low testosterone levels. Investigators gave each man either enzalutamide or abiraterone and tracked whether their PSA levels continued to rise, an indication that the drugs were not working.
Circulating tumor cell (CTC) analyses were conducted using the commercially-available Alere CTC AdnaTest platform (AdnaGen; Langenhagen, Germany). A Prostate Cancer Detect kit was used to make complementary DNA (cDNA) for detection of prostate cancer-associated RNA transcripts using multiplexed polymerase chain reaction (PCR) and the signals were detected by the Agilent Bioanalyzer (Agilent Technologies; Palo Alto, CA, USA). RNA in situ hybridization (RISH) was performed to detect the androgen receptor (AR) and AR-V7 on formalin-fixed paraffin-embedded (FFPE) tissue or cell pellet blocks using the ACD RNAscope 2.0 Brown kit (Advanced Cell Diagnostics; Hayward, CA, USA).
In the enzalutamide group, none of 12 patients whose blood samples tested positive for AR-V7 responded to the drug, compared with 10 responders among 19 men who had no AR-V7 detected. In the abiraterone group, none of six AR-V7-positive patients responded, compared with 17 responders among 25 patients lacking AR-V7. Enzalutamide and abiraterone target proteins called androgen receptors and block the receptors’ ability to activate prostate cancer cells. AR-V7 is a shortened form of the androgen receptor that lacks a binding spot targeted by enzalutamide and abiraterone. AR-V7 is therefore free to manipulate prostate cancer cells’ genetic material, which makes the cancer cells grow and spread.
Emmanuel S. Antonarakis, MD, assistant professor of oncology and lead author of the study said, “Patients whose blood samples contained AR-V7 got no benefit from either enzalutamide or abiraterone. This test could be used before starting enzalutamide or abiraterone therapy, and if the test shows the presence of AR-V7, patients may opt for a different therapy. It could also be used to monitor patients receiving enzalutamide or abiraterone for AR-V7, providing an indication these drugs may not work for much longer.” The study was published on September 3, 2014, in the New England Journal of Medicine.
Related Links:
Johns Hopkins’ Kimmel Cancer Center
AdnaGen
Advanced Cell Diagnostics
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans